Author : Vinod kumar p
Keyword : Osteoarthritis, nsaids, cox/5-lox dual inhibitors, licofelone
Subject : Pharmacology
Article Type : Review article
DOI : 10.18203/2319-2003.ijbcp20211654
Article File : Full Text PDF
Abstract : Osteoarthritis is a progressive joint disease associated with aging in elderly is, characterized by pain, inflammation, and difficulty in movement. The pathways involved in the progression of this disease remain unclear. The mediators, eicosanoids and leukotrienes are produced by COX-1/COX-2 or 5-LOX. Physicians have always used nonsteroidal anti-inflammatory drugs to treat the pain associated with osteoarthritis.A competitive inhibitor of LOX-5 and COX-2 that has both analgesic and anti-inflammatory activity is licofelone;one of the most promising candidates for the treatment of osteoarthritis is under clinical trial in treatment. A significant reduction in cartilage volume was displayed. A significant improvement over baseline on the WOMAC index and GI tolerance was also observed. Improving the symptoms related pain sensation with a happier life. With new strategies in OA, new methods to target pain, inflammation and movement restrictions would be the ultimate goal in patient satisfaction for the future. Licofelone was found to be effective compared to NSAIDs or coxibs in the treatment of OA. Does this mean this could be the answer?
Article by : P VINOD KUMAR
Article add date : 2021-05-20
How to cite : Vinod kumar p. (2021-May-20). Licofelone in osteoarthritis: is this the awaited drug? a systematic review. retrieved from https://www.openacessjournal.com/abstract/734